P53, guardian of the genome, prevents solid tumor growth
(SAN ANTONIO) June 10, 2022 –– Lindalou Trevino was the first patient to enroll in clinical trial PC14586, and because of her favorable response to this new investigational drug, she has renewed hope and a new lease on life.
PC14586 is a first-in-class, oral, small molecule p53 reactivator that is selective for the p53 Y220C mutation in solid tumors. Data presented at the 2022 American Society of Clinical Oncology (ASCO) annual meeting held June 3-7 in Chicago titled, “First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation,” [NCT04585750 on www.clinicaltrials.gov] found the Phase 1/2 trial of PC14586 to be safe and well-tolerated.
Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, is a clinical investigator on the study. He said this investigational therapy is designed to target a specific p53 mutation, referred to as TP53 Y220C, that may be found in a small number of solid tumors. Patients whose tumors have this TP53 Y220C mutation could be eligible to enroll in the clinical study of this investigational therapy. The study is open at NEXT Oncology and other centers in the US.
“p53 plays an important role in cancer because it is essential for regulating DNA repair and cell division, and it has been nicknamed the ‘guardian of the genome,’” said Dr. Tolcher. “By stopping cells with mutated or damaged DNA from dividing, p53 helps prevent the development of tumors.”
Trevino was first diagnosed with omentum cancer in 2008. After a radical hysterectomy, she was in remission for nearly 10 years. In 2017, she was referred to Dr. Tolcher after she no longer responded to all standard therapies for her endometrial cancer. Her doctor had a tumor genetics test performed and she had the p53 Y220C mutation.
“When I learned about this trial, I was ready to get started because it offered me a new hope,” Trevino said. “I haven’t been able to take a trip with my family for years to due cancer treatments and the side effects. But I just got back from a beach to South Padre Island and am still feeling great.”
Trevino remains the longest patient enrolled on this trial, and after nearly two years of treatment, she is back to living her life despite the cancer and remains hopeful.
Trevino’s daughter, Debbie Esteves was a little more hesitant because she didn’t understand the research process and her limited knowledge led her to believe it just an experiment.
Trevino, 75, has been on several trials since 2017. She said being on trial PC14586 makes life with cancer livable because it’s a simple pill she can take at home and she has had no side effects. She travels to San Antonio from Elmendorf every three weeks to see her doctors at NEXT Oncology.
“I’m hoping it will continue to work, but if it doesn’t, I will certainly try another trial,” said Trevino.
About NEXT Oncology
NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT is partnered with
Texas Oncology, the largest private oncology practice in the United States with more than 400 referring oncologists and US Oncology, a network of independent, community-based oncologists in the U.S. This formidable size and reach provide NEXT unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.
PMV Pharma Disclaimers:
- PC14586 has not been approved by the US Food and Drug Administration for safety and effectiveness, and is undergoing early clinical study to verify its safety and effectiveness.
- PC14586 is only intended for use by a pre-identified, select group of cancer patients who have a rare genetic mutation. It is not intended for use in all cancer patients.